Natalie Breeden
Surgical · Boston, MANPI 1063140895
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $825 of the $1,150 with a category attached, or 71.7%. 11 manufacturers reported payments, led by Arthrex at 42.3% of the total. Reporting peaked in 2023 at $597 and has fallen 61.0% since, to $233 in 2025.
Across 37 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$486
- Smith+Nephew$163
- Si-bone, Inc.$126
- Pacira Pharmaceuticals Incorporated$117
- Stryker$70
- Vertex$60
- plus $129 from 5 others
What the payments were for
- Travel & lodging$32528%
- Food & beverage$82572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 13 | $486 |
| Smith+Nephew | 7 | $163 |
| Si-bone, Inc. | 3 | $126 |
| Pacira Pharmaceuticals Incorporated | 4 | $117 |
| Stryker | 1 | $70 |
| Vertex | 3 | $60 |
| Johnson & Johnson | 1 | $41 |
| Bioventus LLC | 2 | $36 |
| Solventum Corporation | 1 | $20 |
| Orthofix Medical, Inc. | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $15 |
How this compares
$1,150 in reported general payments places this provider in the 80th percentile of 312 surgical providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 45 | $155 |
| Methocarbamol | 21 | $80 |
Paid to pharmacies, not to this prescriber.
Other surgical in Boston
- Michael LlewellynBoston$8K
- Dana GoldenseBoston$5K
- Madison AltwiesBoston$5K
- Jenna SheridanBoston$4K
- Khare WilsonBoston$2K
- John MacropoulosBoston$2K
- Emilia FuscoBoston$1K
- Alexandra JurellerBoston$1K
- Gregory DeconciliisWaltham$27K
- Lampros MinosWaltham$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.